Aurinia Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Aurinia Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Aurinia Pharmaceuticals Inc Strategy Report
- Understand Aurinia Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals) is a commercial-stage biopharmaceutical company. The company pipeline product includes voclosporin, lupkynis, AUR200 and AUR300. Its lupkynis is an orally administered CNI immunosuppressant, to treat adult patients with active lupus nephritis. Aurinia Pharmaceuticals voclosporin is used in clinical studies in patients with psoriasis, kidney transplantation, uveitis and dry eye syndrome indications. The company's AUR300 reduces M2 dysregulation and decreases inflammatory cytokines and finds clinical applications for autoimmune and fibrotic diseases. It collaborates with Otsuka Pharmaceutical Co., Ltd for the development and commercialization of oral voclosporin. The company operates in Canada and the US. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.
Aurinia Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Voclosporin: |
Lupus Nephritis (LN) |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Plans/Strategy | In June, the company announced its plans to consider a wide range of options for the company including a potential sale, merger, or other strategic transaction. |
2023 | Regulatory Approval | In May, the company announced that Swissmedic approved marketing authorization of LUPKYNIS (voclosporin) for the development and commercialization of voclosporin for the treatment of lupus nephritis (LN). |
2023 | Others | In April, the company issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. |
Competitor Comparison
Key Parameters | Aurinia Pharmaceuticals Inc | AbbVie Inc | BioMarin Pharmaceutical Inc | Zymeworks Inc | Cipher Pharmaceuticals Inc |
---|---|---|---|---|---|
Headquarters | Canada | United States of America | United States of America | United States of America | Canada |
City | Victoria | North Chicago | Novato | Middletown | Mississauga |
State/Province | British Columbia | Illinois | California | Delaware | Ontario |
No. of Employees | 300 | 50,000 | 3,401 | 272 | 6 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Daniel G. Billen | Chairman | Executive Board | 2023 | - |
Peter Greenleaf | Chief Executive Officer; President; Director | Executive Board | 2019 | 53 |
Joe Miller | Chief Financial Officer | Senior Management | 2020 | 49 |
Stephen Robertson | General Counsel; Executive Vice President; Secretary; Chief Compliance Officer | Senior Management | 2020 | 41 |
Scott Habig | Chief Commercial Officer | Senior Management | 2022 | 63 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer